|
Rao Hanyu Dr. Hanyu Rao is a Research Associate at the School of Biomedical Engineering, Shanghai Jiao Tong University. He received his Ph.D. in Science from the same school in September 2021 and joined the faculty in the same year. His primary research focuses on the mechanistic investigation of tumor-related genes in tumor pathogenesis, and the development of cell-based immunotherapy utilizing mesenchymal stem cells as cellular carriers. To date, he has published 17 academic papers in leading SCI journals in the oncology field, and 1 Chinese invention patent has been granted to him. He has participated in the joint research project between Shanghai Jiao Tong University and the University of Sydney, and completed a visiting scholarship at the School of Biomedical Engineering, the University of Sydney, Australia in 2019. In terms of research grants, he has served as the Principal Investigator (PI) for 1 Youth Program (Category C) and 1 General Program of the National Natural Science Foundation of China (NSFC). Additionally, he has taken part in a total of 6 research projects, including NSFC Key Programs, NSFC General Programs, and projects funded by the Science and Technology Commission of Shanghai Municipality. |
1. Rao H, Wang A, Xu Y, Feng W, Ma C, Wang Z, Zhang W, Su W, Xiao X, Gao WQ, Ding X*, Li L*. Ribosome Homeostasis Regulated by SETD2 Preserves Intestinal Epithelial Barrier. Adv. Sci. (Weinh). 2026;13(16):e08168.
2. Rao H, Liu C, Wang A, Ma C, Xu Y, Ye T, Su W, Zhou P, Gao WQ, Li L*, Ding X*. SETD2 Deficiency Accelerates Sphingomyelin Accumulation and Promotes the Development of Renal Cancer. Nat. Commun. 2023;14(1):7572.
3. Rao H, Li X, Liu M, Liu J, Feng W, Tang H, Xu J, Gao WQ*, Li L*. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma. Cancer Res. 2021;81(13):3554-3567.
4. Rao H, Li X, Liu M, Liu J, Li X, Xu J, Li L*, Gao WQ*. Di-Ras2 Promotes Renal Cell Carcinoma Formation by Activating the Mitogen-Activated Protein Kinase Pathway in the Absence of von Hippel-Lindau Protein. Oncogene. 2020;39(19):3853-3866.
5. Bi X, Ma B, Liu W, Gao WQ, Ye J*, Rao H*. Transcriptome-Aligned Metabolic Profiling by SERSome Reflects Biological Changes Following Mesenchymal Stem Cells Expansion. Stem Cell Res. Ther. 2024;15(1):467.
6. Liu M, Rao H, Liu J, Li X, Feng W, Gui L, Tang H, Xu J, Gao WQ*, Li L*. The Histone Methyltransferase SETD2 Modulates Oxidative Stress to Attenuate Experimental Colitis. Redox Biol. 2021;43:102004.
7. Xu Y, Wang Z, Feng W, Rao H, Wang D, Zhang W, Aji R, Liu N, Li J, Xiao X, Gao WQ, Li L*. Histone 3 Lysine 36 Trimethylation by SETD2 Shapes an Epigenetic Landscape in Intestinal Stem Cells to Orchestrate Lipid Metabolism and Attenuate Cell Senescence. Cell Death Dis. 2026;17(1):273.
8. Zhang W, Feng W, Ma C, Rao H, Liu C, Xu Y, Liu N, Wang Z, Aji R, Han T, Gao WQ, Xiao X, Li L*. NSD2 Inhibits the Expression of PD-L1 via Oxidative Phosphorylation to Control Immune Surveillance in Hepatocellular Carcinoma. Cell Death Dis. 2026;17(1):284.
9. Aji R, Xu Y, Wang Z, Feng W, Gui L, Rao H, Zhang W, Liu N, Gao WQ, Li L*. Targeted Delivery of Grem1 and IL-10 Separately by Mesenchymal Stem Cells Effectively Mitigates SETD2-Deficient Inflammatory Bowel Disease. Theranostics. 2025;15(6):2215-2228.
10. Feng W, Liu N, Liu C, Rao H, Chen Z, Zhang W, Xu Y, Aji R, Wang Z, Gao WQ, Li L*. NSD2 Promotes Cell Durotaxis and Drives the Transition from Polycystic Kidney Disease to Tubulocystic Renal Cell Carcinoma Through Integrin/FAK/AKT Signaling. Oncogene. 2025;44(37):3437-3448.
11. Feng W, Niu N, Lu P, Chen Z, Rao H, Zhang W, Ma C, Liu C, Xu Y, Gao WQ, Xue J, Li L. Multilevel Regulation of NF-κB Signaling by NSD2 Suppresses Kras-Driven Pancreatic Tumorigenesis. Adv. Sci. 2024;11(30):2198-3844.
12. Xu Y, Xiao X, Ma C, Wang Z, Feng W, Rao H, Zhang W, Liu N, Aji R, Meng X, Gao WQ, Li L. Epithelial NSD2 Maintains FMO-Mediated Taurine Biosynthesis to Prevent Intestinal Barrier Disruption. Clin. Transl. Med. 2024;14(12):e70128.
13. Feng W, Ma C, Rao H, Zhang W, Liu C, Xu Y, Aji R, Wang Z, Xu J, Gao WQ, Li L*. SETD2 Deficiency Promotes Gastric Tumorigenesis Through Inhibiting the SIRT1/FOXO Pathway. Cancer Lett. 2023;579:216470.
14. Liu C, Ni L, Li X, Rao H, Feng W, Zhu Y, Zhang W, Ma C, Xu Y, Gui L, Wang Z, Aji R, Xu J, Gao WQ*, Li L*. SETD2 Deficiency Promotes Renal Fibrosis Through the TGF-β/Smad Signalling Pathway in the Absence of VHL. Clin. Transl. Med. 2023;13(11):e1468.
15. Ma C, Liu M, Feng W, Rao H, Zhang W, Liu C, Xu Y, Wang Z, Teng Y, Yang X, Ni L, Xu J, Gao WQ, Lu B, Li L*. Loss of SETD2 Aggravates Colorectal Cancer Progression Caused by SMAD4 Deletion Through the RAS/ERK Signalling Pathway. Clin. Transl. Med. 2023;13(11):e1475.
16. Li X, Liu C, Zhu Y, Rao H, Liu M, Gui L, Feng W, Tang H, Xu J, Gao WQ, Li L. SETD2 Epidermal Deficiency Promotes Cutaneous Wound Healing via Activation of AKT/mTOR Signalling. Cell Prolif. 2021;54(6):e13045.
17. Liu J, Feng W, Liu M, Rao H, Li X, Teng Y, Yang X, Xu J, Gao WQ, Li L. Stomach-Specific c-Myc Overexpression Drives Gastric Adenoma in Mice Through AKT/Mammalian Target of Rapamycin Signaling. Bosn. J. Basic Med. Sci. 2021;21(4):434-446.
E-mail：raohanyu@sjtu.edu.cn
address：上海交通大学市徐汇区
交大主页